ACR appropriateness Criterias ® early-stage non-small-cell lung cancer

Gregory M.M. Videtic, Joe Yujiao Chang, Indrin J. Chetty, Mark E. Ginsburg, Larry L. Kestin, Feng Ming Kong, Brian E. Lally, Billy W. Loo, Benjamin Movsas, Thomas E. Stinchcombe, Henning Willers, Kenneth E. Rosenzweig

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Early-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)201-207
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume37
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Radiology
Lung Neoplasms
Guidelines
Radiosurgery
Expert Testimony
Therapeutics
Standard of Care
Comorbidity
Consensus
Decision Making
Lymph Nodes

Keywords

  • Adjuvant
  • Early-stage non-small-cell lung cancer
  • Medical operability
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Videtic, G. M. M., Chang, J. Y., Chetty, I. J., Ginsburg, M. E., Kestin, L. L., Kong, F. M., ... Rosenzweig, K. E. (2014). ACR appropriateness Criterias ® early-stage non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 37(2), 201-207. https://doi.org/10.1097/COC.0000000000000013

ACR appropriateness Criterias ® early-stage non-small-cell lung cancer. / Videtic, Gregory M.M.; Chang, Joe Yujiao; Chetty, Indrin J.; Ginsburg, Mark E.; Kestin, Larry L.; Kong, Feng Ming; Lally, Brian E.; Loo, Billy W.; Movsas, Benjamin; Stinchcombe, Thomas E.; Willers, Henning; Rosenzweig, Kenneth E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 37, No. 2, 01.01.2014, p. 201-207.

Research output: Contribution to journalReview article

Videtic, GMM, Chang, JY, Chetty, IJ, Ginsburg, ME, Kestin, LL, Kong, FM, Lally, BE, Loo, BW, Movsas, B, Stinchcombe, TE, Willers, H & Rosenzweig, KE 2014, 'ACR appropriateness Criterias ® early-stage non-small-cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 37, no. 2, pp. 201-207. https://doi.org/10.1097/COC.0000000000000013
Videtic, Gregory M.M. ; Chang, Joe Yujiao ; Chetty, Indrin J. ; Ginsburg, Mark E. ; Kestin, Larry L. ; Kong, Feng Ming ; Lally, Brian E. ; Loo, Billy W. ; Movsas, Benjamin ; Stinchcombe, Thomas E. ; Willers, Henning ; Rosenzweig, Kenneth E. / ACR appropriateness Criterias ® early-stage non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2014 ; Vol. 37, No. 2. pp. 201-207.
@article{5cf5733ea0e240ce95c7be28cc0dbf0e,
title = "ACR appropriateness Criterias {\circledR} early-stage non-small-cell lung cancer",
abstract = "Early-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15{\%} to 20{\%} of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.",
keywords = "Adjuvant, Early-stage non-small-cell lung cancer, Medical operability, Radiotherapy, Surgery",
author = "Videtic, {Gregory M.M.} and Chang, {Joe Yujiao} and Chetty, {Indrin J.} and Ginsburg, {Mark E.} and Kestin, {Larry L.} and Kong, {Feng Ming} and Lally, {Brian E.} and Loo, {Billy W.} and Benjamin Movsas and Stinchcombe, {Thomas E.} and Henning Willers and Rosenzweig, {Kenneth E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/COC.0000000000000013",
language = "English (US)",
volume = "37",
pages = "201--207",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - ACR appropriateness Criterias ® early-stage non-small-cell lung cancer

AU - Videtic, Gregory M.M.

AU - Chang, Joe Yujiao

AU - Chetty, Indrin J.

AU - Ginsburg, Mark E.

AU - Kestin, Larry L.

AU - Kong, Feng Ming

AU - Lally, Brian E.

AU - Loo, Billy W.

AU - Movsas, Benjamin

AU - Stinchcombe, Thomas E.

AU - Willers, Henning

AU - Rosenzweig, Kenneth E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Early-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

AB - Early-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for earlystage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically perable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidencebased guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

KW - Adjuvant

KW - Early-stage non-small-cell lung cancer

KW - Medical operability

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84900399871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900399871&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000013

DO - 10.1097/COC.0000000000000013

M3 - Review article

C2 - 25180631

AN - SCOPUS:84900399871

VL - 37

SP - 201

EP - 207

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -